Ottawa – May 30, 2022 – The Canadian Centre for Ethics in Sport (CCES) announced today that Donovan Burgmaier, a U SPORTS football athlete affiliated with the University of Alberta, received an additional three-year sanction for an anti-doping rule violation. The athlete’s urine sample, collected during in-competition doping control on October 30, 2021, revealed the presence of dehydrochlormethyltestosterone, a prohibited anabolic agent.

Mr. Burgmaier signed an Early Admission and Acceptance Form, thereby admitting to a violation, waiving his right to a hearing, and accepting all proposed consequences. In accordance with Canadian Anti-Doping Program (CADP) rule 10.9.3.2, the now-confirmed Presence violation and Mr. Burgmaier’s prior Use violation (involving the same anabolic agent) are to be treated as a single first violation and the related sanctions will be served consecutively. As a result, the sanction for this Presence violation will begin following the completion of the sanction for the Use violation and will end no earlier than January 25, 2028.

During the sanction period, the athlete, who resides in Edmonton, Alberta, remains ineligible to participate in any capacity with any sport signatory to the CADP, including training with teammates.

In compliance with rule 8.4 of the CADP, the CCES’s file outcome summary can be found in the Canadian Sport Sanction Registry.

About the CCES

The CCES works collaboratively to ensure Canadians have a positive sport experience. Through its programs, the CCES manages unethical issues in sport, protects the integrity of Canadian sport, and promotes True Sport to activate values-based sport on and off the field of play. The CCES is an independent, national, not-for profit organization that is responsible for the administration of the CADP. Under the CADP rules, the CCES makes public every anti-doping rule violation. The CCES acknowledges funding, in part, from the Government of Canada. For more information, visit cces.ca, follow us on TwitterFacebook, or Instagram.

 

For further information, please contact:

+1 613-521-3340 x3233
[email protected]

See Also...